Esperion Therapeutics Income Statement (2012-2026) | ESPR

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	40.66M	14.41M	15.40M	18.84M	18.84M	18.98M	18.82M	24.33M	25.79M	33.97M	32.25M	137.74M	73.83M	51.63M	69.11M	65.00M	82.39M	87.31M	168.45M	80.10M
Cost of Revenue (Quarter)	1.80M	5.56M	5.08M	7.12M	9.18M	6.51M	4.16M	11.65M	6.79M	13.38M	11.45M	10.07M	15.61M	17.29M	25.63M	31.54M	28.54M	41.29M		34.57M
Gross Profit (Quarter)	38.86M	8.85M	10.33M	11.71M	9.66M	12.47M	14.66M	12.68M	19.00M	20.59M	20.80M	127.66M	58.23M	34.35M	43.48M	33.46M	53.84M	46.02M		45.53M
Operating items
Research & Development (Quarter)	25.07M	25.33M	27.62M	24.32M	32.43M	29.14M	33.03M	31.38M	22.10M	14.88M	17.74M	13.40M	11.46M	10.40M	10.98M	12.56M	7.24M	14.13M	13.93M	8.99M
Selling, General & Administrative (Quarter)	46.32M	39.27M	38.34M	30.38M	29.61M	24.95M	24.14M	29.90M	33.96M	33.24M	45.42M	41.99M	44.19M	39.98M	36.92M	43.00M	39.51M	41.85M	41.43M	43.12M
Other Operating Expenses (Quarter)	1.80M	5.56M	5.08M	7.12M	9.18M	6.51M	4.16M	11.65M	6.79M	13.38M	-217.18M	10.07M	15.61M	17.29M	-183.68M	31.54M	28.54M	41.29M	27.85M	34.57M
Operating Expenses (Quarter)	73.19M	70.15M	71.03M	61.83M	71.22M	60.60M	61.33M	72.93M	62.84M	61.50M	-154.01M	65.47M	71.25M	67.66M	-135.78M	87.09M	75.29M	97.27M	83.21M	86.69M
Operating Income (Quarter)	-32.53M	-55.74M	-55.63M	-42.99M	-52.38M	-41.62M	-42.51M	-48.60M	-37.06M	-27.53M	-42.37M	72.27M	2.58M	-16.03M	-4.42M	-22.10M	7.09M	-9.96M	85.23M	-6.58M
EBIT (Quarter)	-32.53M	-55.74M	-55.63M	-42.99M	-52.38M	-41.62M	-42.51M	-48.60M	-37.06M	-27.53M	-42.37M	72.27M	2.58M	-16.03M	-4.42M	-22.10M	7.09M	-9.96M	85.23M	-6.58M
Non-operating items
Other Non Operating Income (Quarter)	0.01M	0.01M	3.94M	0.32M	0.32M	0.66M	1.35M	1.27M	1.66M	1.28M	5.29M	2.78M	-53.20M	1.58M	-1.72M	1.07M			-2.42M	1.18M
Non Operating Income (Quarter)	0.01M	0.01M	3.94M	0.32M	0.32M	0.66M	1.35M	1.27M	1.66M	1.28M	1.08M	2.78M	2.45M	1.58M	1.21M	1.07M	0.67M	0.68M	1.07M	1.18M
Net income details
EBT (Quarter)	-43.68M	-69.40M	-69.06M	-57.05M	-66.64M	-55.78M	-56.84M	-62.99M	-51.59M	-42.53M	-57.42M	58.24M	-11.14M	-31.11M	-29.08M	-41.53M	-13.39M	-32.01M	62.60M	-26.38M
Profit After Tax (Quarter)	-43.67M	-69.39M	-65.12M	-56.73M	-66.32M	-55.12M	-55.49M	-61.72M	-49.94M	-41.25M	-56.34M	61.02M	-61.92M	-29.52M	-21.32M	-40.45M	-12.72M	-31.33M	61.83M	-25.20M
Income from Continuing Operations (Quarter)	-43.68M	-69.40M	-69.06M	-57.05M	-66.64M	-55.78M	-56.84M	-62.99M	-51.59M	-42.53M	-57.42M	58.24M	-11.14M	-31.11M	-29.08M	-41.53M	-13.39M	-32.01M	62.60M	-26.38M
Consolidated Net Income (Quarter)	-43.68M	-69.40M	-69.06M	-57.05M	-66.64M	-55.78M	-56.84M	-62.99M	-51.59M	-42.53M	-57.42M	58.24M	-11.14M	-31.11M	-29.08M	-41.53M	-13.39M	-32.01M	62.60M	-26.38M
Income towards Parent Company (Quarter)	-43.68M	-69.40M	-69.06M	-57.05M	-66.64M	-55.78M	-56.84M	-62.99M	-51.59M	-42.53M	-57.42M	58.24M	-11.14M	-31.11M	-29.08M	-41.53M	-13.39M	-32.01M	62.60M	-26.38M
Net Income towards Common Stockholders (Quarter)	-43.68M	-69.40M	-69.06M	-57.05M	-66.64M	-55.78M	-56.84M	-62.99M	-51.59M	-42.53M	-57.42M	58.24M	-11.14M	-31.11M	-29.08M	-41.53M	-13.39M	-32.01M	62.60M	-26.38M
Additional items
EPS (Basic) (Quarter)	-1.67	-2.62	-1.53	-0.93	-1.05	-0.81	-0.74	-0.79	-0.46	-0.37	-0.50	0.36	-0.33	-0.15	-0.11	-0.21	-0.06	-0.16	0.32	-0.10
EPS (Weighted Average and Diluted) (Quarter)	-1.67	-2.62	-1.53	-0.93	-1.05	-0.81	-0.74	-0.79	-0.46	-0.37	-0.50	0.34	-0.33	-0.15	-0.11	-0.21	-0.06	-0.16	0.32	-0.10
Shares Outstanding (Weighted Average) (Quarter)	26.23M	26.46M	28.90M	60.95M	62.10M	67.81M	66.41M	78.44M	93.93M	111.87M	103.11M	169.26M	179.03M	194.93M	187.18M	196.13M	26.07M	200.74M	18.89M	251.35M
Shares Outstanding (Diluted Average) (Quarter)	26.23M	26.23M	28.90M	60.95M	62.10M	64.02M	66.41M	78.44M	109.24M	111.87M	103.11M	189.64M	188.79M	184.37M	187.18M	196.13M	197.55M	198.15M	207.87M	251.35M
EBITDA (Quarter)	-43.67M	-69.39M	-65.15M	-56.96M	-66.36M	-54.91M	-55.40M	-61.72M	-49.93M	-41.25M	-56.34M	61.02M	-61.92M	-29.52M	-21.32M	-40.45M	-12.72M	-31.33M	61.83M	-25.20M
Interest Expenses (Quarter)	11.14M	13.65M	13.43M	14.06M	14.27M	14.15M	14.33M	14.39M	14.54M	14.99M	15.06M	14.02M	13.72M	15.08M	24.66M	19.43M	20.49M	22.05M	22.64M	19.80M

Research Tools

Esperion Therapeutics Income Statement (2012-2026) | ESPR

Create an account

Sign In

Reset Password